Literature DB >> 12173341

Survival analysis with p27 expression and apoptosis appears to estimate the prognosis of patients with synovial sarcoma more accurately.

Shigeto Kawauchi1, Yoshinari Goto, Koichiro Ihara, Tomoko Furuya, Atsunori Oga, Masazumi Tsuneyoshi, Shinya Kawai, Kohsuke Sasaki.   

Abstract

BACKGROUND: Although recent experimental studies have implicated p27 as a regulator of apoptosis in a number of neoplasms, to the authors' knowledge the relation between p27 expression and apoptosis has not yet been established in synovial sarcoma.
METHODS: The relation between p27, apoptosis, and clinicopathologic features were examined in 62 synovial sarcoma cases.
RESULTS: p27 expression was found to be correlated inversely with the extent of apoptosis in synovial sarcomas. On survival analysis, p27 expression was found to be a significant and independent prognostic factor. Although the extent of apoptosis was determined to be prognostically significant, it failed to retain an independent and significant value on multivariate analysis. The combination of p27 expression and apoptosis allowed for the more accurate estimation of prognosis in patients with synovial sarcoma than either parameter alone.
CONCLUSIONS: A combination of p27 expression and extent of apoptosis permitted the more accurate estimation ofy the prognosis of patients with synovial sarcoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173341     DOI: 10.1002/cncr.10556

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  Diagnosis and management of synovial sarcoma.

Authors:  R Lor Randall; Kathryn L S Schabel; Ying Hitchcock; David E Joyner; Karen H Albritton
Journal:  Curr Treat Options Oncol       Date:  2005-11

2.  A case of renal synovial sarcoma: complete remission was induced by chemotherapy with doxorubicin and ifosfamide.

Authors:  Soo-Jin Park; Hyun-Kun Kim; Chan-Kyu Kim; Sung-Kyu Park; Eun-Suk Go; Min-Eui Kim; Dae Sik Hong
Journal:  Korean J Intern Med       Date:  2004-03       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.